LLY

1,074.05

-2.81%↓

JNJ

204.84

-1.39%↓

ABBV

226.66

-0.39%↓

UNH

331.47

+0.54%↑

AZN

92.61

-0.81%↓

LLY

1,074.05

-2.81%↓

JNJ

204.84

-1.39%↓

ABBV

226.66

-0.39%↓

UNH

331.47

+0.54%↑

AZN

92.61

-0.81%↓

LLY

1,074.05

-2.81%↓

JNJ

204.84

-1.39%↓

ABBV

226.66

-0.39%↓

UNH

331.47

+0.54%↑

AZN

92.61

-0.81%↓

LLY

1,074.05

-2.81%↓

JNJ

204.84

-1.39%↓

ABBV

226.66

-0.39%↓

UNH

331.47

+0.54%↑

AZN

92.61

-0.81%↓

LLY

1,074.05

-2.81%↓

JNJ

204.84

-1.39%↓

ABBV

226.66

-0.39%↓

UNH

331.47

+0.54%↑

AZN

92.61

-0.81%↓

Search

Penumbra Inc

Open

SectorHealthcare

294.68 -0.01

Overview

Share price change

24h

Current

Min

290.72

Max

297.16

Key metrics

By Trading Economics

Income

581K

46M

Sales

15M

355M

P/E

Sector Avg

70.979

79.874

Profit margin

12.927

Employees

4,500

EBITDA

4M

55M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+4.04% upside

Market Stats

By TradingEconomics

Market Cap

2.9B

12B

Previous open

294.69

Previous close

294.68

News Sentiment

By Acuity

50%

50%

168 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Penumbra Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lis 2025, 16:49 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 lis 2025, 15:32 UTC

Acquisitions, Mergers, Takeovers

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 lis 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 lis 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 lis 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 lis 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 lis 2025, 15:54 UTC

Acquisitions, Mergers, Takeovers

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 lis 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 lis 2025, 15:43 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 lis 2025, 15:42 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 lis 2025, 15:41 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 lis 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 lis 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 lis 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 lis 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 lis 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 lis 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 lis 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27 lis 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 lis 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27 lis 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27 lis 2025, 11:07 UTC

Earnings

Genting: Positive About Prospects Over Longer Term

27 lis 2025, 11:06 UTC

Earnings

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 lis 2025, 11:04 UTC

Earnings

Genting: International Travel Demand Expected to Remain Resilient

27 lis 2025, 11:04 UTC

Earnings

Genting: Global Growth Expected to Remain Subdued

27 lis 2025, 11:04 UTC

Earnings

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 lis 2025, 10:59 UTC

Earnings

Genting Bhd 3Q Net Profit Fell 86% on Year

27 lis 2025, 10:58 UTC

Earnings

Genting Bhd 3Q Rev Rose 14% on Year

27 lis 2025, 10:56 UTC

Earnings

Genting Bhd 3Q Net MYR30.3M

27 lis 2025, 10:56 UTC

Earnings

Genting Bhd 3Q EPS MYR0.0079

Peer Comparison

Price change

Penumbra Inc Forecast

Price Target

By TipRanks

4.04% upside

12 Months Forecast

Average 307.92 USD  4.04%

High 355 USD

Low 266 USD

Based on 13 Wall Street analysts offering 12 month price targets forPenumbra Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

288.28 / 292.9394Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

168 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat